User profiles for Virangika K. Wimalasena

Virangika Wimalasena

Johns Hopkins University
Verified email at jhmi.edu
Cited by 232

[PDF][PDF] Using chemical epigenetics to target cancer

VK Wimalasena, T Wang, LH Sigua, AD Durbin, J Qi - Molecular cell, 2020 - cell.com
Transcription is epigenetically regulated by the orchestrated function of chromatin-binding
proteins that tightly control the expression of master transcription factors, effectors, and …

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma

AD Durbin, T Wang, VK Wimalasena, MW Zimmerman… - Cancer discovery, 2022 - AACR
EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding
TFAP2β. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential …

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma

…, L Wu, A Ray, S Picaud, D Li, VK Wimalasena… - Leukemia, 2019 - nature.com
Proteasome inhibition is an effective treatment for multiple myeloma (MM); however, targeting
different components of the ubiquitin–proteasome system (UPS) remains elusive. Our RNA…

Lysine demethylase 5A Is required for MYC-driven transcription in multiple myeloma

…, C Pei, T Masuda, C Johansson, VK Wimalasena… - Blood cancer …, 2021 - AACR
We delineate the function of KDM5A in activating the MYC-driven transcriptional landscape.
We develop a cell-permeable KDM5 inhibitor to define the activating role of KDM5A on MYC …

Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors

A Muthengi, VK Wimalasena, HO Yosief… - Journal of medicinal …, 2021 - ACS Publications
The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned
from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET …

Colicin E1 opens its hinge to plug TolC

…, JJ Stevens, AL Calkins, AP Ikujuni, VK Wimalasena… - Elife, 2022 - elifesciences.org
The double membrane architecture of Gram-negative bacteria forms a barrier that is
impermeable to most extracellular threats. Bacteriocin proteins evolved to exploit the accessible, …

Exploiting polarity and chirality to probe the Hsp90 C-terminus

LK Forsberg, RE Davis, VK Wimalasena… - Bioorganic & medicinal …, 2018 - Elsevier
Inhibition of the Hsp90 C-terminus is an attractive therapeutic approach for the treatment of
cancer. Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically …

N-Methyl-4-phenylpyridinium Scaffold-Containing Lipophilic Compounds Are Potent Complex I Inhibitors and Selective Dopaminergic Toxins

…, VK Wimalasena, K Wimalasena - ACS chemical …, 2019 - ACS Publications
Although the exact cause or causes of Parkinson’s disease (PD) are not fully understood, it
is believed that environmental factors play a major role. The discovery that a synthetic …

Deepening biomedical research training: Community-Building Wellness Workshops for Post-Baccalaureate Research Education Program (PREP) Trainees

…, MQ Beckett, V Clark, J Jeffery, VK Wimalasena… - bioRxiv, 2024 - biorxiv.org
Problem: All trainees, especially those from historically minoritized backgrounds, experience
stresses that may reduce their continuation in science, technology, engineering, math, and …

Colicin E1 Fragments Potentiate Antibiotics by Plugging TolC

SJ Budiardjo, JJ Deay, AL Calkins, VK Wimalasena… - bioRxiv, 2019 - biorxiv.org
The double membrane architecture of Gram-negative bacteria forms a barrier that is effectively
impermeable to extracellular threats. Accordingly, researchers have shown increasing …